Oncology Institute (TOIIW) EBIT (2020 - 2026)

Oncology Institute has reported EBIT for 7 years, with the latest figure at -$6.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 34.29% year-over-year to -$6.5 million; the trailing twelve-month figure through Mar 2026 stood at -$32.7 million (up 37.21% YoY), and the FY2025 full-year result was -$36.1 million, up 39.98% from the prior year.
• EBIT for Q1 2026 stood at -$6.5 million, up from -$6.9 million in the prior quarter.
• The five-year high for EBIT was -$6.5 million in Q1 2026, with the low at -$32.9 million in Q1 2023.
• Historically, EBIT has averaged -$15.4 million across 5 years, with a median of -$14.9 million in 2023.
• Annual changes were most pronounced in 2022 — EBIT tumbled 1540.14% — and 2024, when it surged 45.32%.
• Oncology Institute's EBIT stood at -$25.1 million in 2022, then soared by 39.04% to -$15.3 million in 2023, then gained by 21.97% to -$11.9 million in 2024, then jumped by 42.1% to -$6.9 million in 2025, then rose by 5.7% to -$6.5 million in 2026.
• The last three EBIT figures came in at -$6.5 million (Q1 2026), -$6.9 million (Q4 2025), and -$8.1 million (Q3 2025), per Business Quant data.